Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-κB-NLRP3 inflammasome signaling pathway

Wenhua Gan,Xiaohe Li,Yunyao Cui,Ting Xiao,Rui Liu,Ming Wang,Yiying Wei,Mengqi Cui,Shanfa Ren,Kaiyue Helian,Wen Ning,Honggang Zhou,Cheng Yang
DOI: https://doi.org/10.1016/j.intimp.2020.107230
IF: 5.714
2021-01-01
International Immunopharmacology
Abstract:<p>Inflammation is a defense response of the body to stimuli. Lung injury caused by external stimuli can stimulate inflammatory cells to accumulate at the site of injury and secrete cytokines. Pinocembrin is a flavonoid with anti-inflammatory effects. Based on previous studies, we further explored the anti-inflammatory mechanisms of pinocembrin in vitro and in vivo. <em>In vitro</em> studies indicated that pinocembrin inhibited lipopolysaccharide (LPS)-stimulated inflammatory response in macrophages. <em>In vivo</em> studies also showed that pinocembrin could reduce LPS and bleomycin (BLM) induced lung inflammatory response in mice. Further mechanistic studies indicated that pinocembrin could regulate the TLR4-NF-κB signaling pathway and suppressed the activation and assembly of NLRP3 inflammasomes. In summary, pinocembrin could relieve pulmonary inflammatory response induced by LPS and BLM mainly via inhibiting TLR4-NF-κB-NLRP3 inflammasome axis. These results contribute to the understanding of the anti-inflammatory mechanisms of pinocembrin and serve as reference for future research on pinocembrin.</p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?